Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry-Reference-Cited by-同舟云学术

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry

Published:2020-10-05 Issue:11 Volume:11 Page:3346-3356
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Brat Kristian¹²,Bratova Monika¹²^ORCID,Skrickova Jana¹²,Barinova Magda³,Hurdalkova Karolina³,Pesek Milos⁴⁵,Havel Libor⁶,Koubkova Leona⁷⁸,Hrnciarik Michal⁹¹⁰,Krejci Jana¹¹,Fischer Ondrej¹²¹³,Zemanova Milada¹⁴¹⁵,Coupkova Helena¹⁶,Svaton Martin⁴⁵

Affiliation:

1. Department of Respiratory Diseases University Hospital Brno Brno Czech Republic

2. Faculty of Medicine Masaryk University Brno Czech Republic

3. Institute of Biostatistics and Analyses, Ltd. Brno Czech Republic

4. Department of Pneumology University Hospital Pilsen Pilsen Czech Republic

5. Faculty of Medicine Charles University in Prague Pilsen Czech Republic

6. Department of Respiratory Medicine Thomayer Hospital Prague Czech Republic

7. Department of Pneumology University Hospital Motol Prague Czech Republic

8. 2nd Faculty of Medicine Charles University Prague Czech Republic

9. Department of Pneumology University Hospital Hradec Kralove Hradec Kralove Czech Republic

10. Faculty of Medicine Charles University in Prague Hradec Kralove Czech Republic

11. Department of Pneumology and Thoracic Surgery Bulovka Hospital Prague Czech Republic

12. Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic

13. Faculty of Medicine Palacky University Olomouc Czech Republic

14. Department of Oncology General Teaching Hospital Prague Czech Republic

15. 1st Faculty of Medicine Charles University Prague Czech Republic

16. Clinic of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Funder

Ministerstvo Zdravotnictví Ceské Republiky

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13679

Reference56 articles.

1. Progress in the Management of Advanced Thoracic Malignancies in 2017

2. Non‐small cell lung cancer as a chronic disease ‐ a prospective study from the Czech TULUNG registry;Bratova M;In Vivo,2020

3. Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer;Cramer‐van der Welle CM;Eur Respir J,2019

4. Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

5. Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer;Journal of Cancer Research and Clinical Oncology;2023-09-28

2. Experience with the treatment of lung cancer from real clinical practice - findings from registries TULUNG and LUCAS;Onkologie;2023-03-01

3. Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada;Current Oncology;2022-10-26

4. The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma;Bosnian Journal of Basic Medical Sciences;2022-10-23

5. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group;Cancer Treatment and Research Communications;2022